Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has clarified that details regarding its reported KRW 300.0B drug product (DP) plant investment in Yesan, Chungnam remain unconfirmed following a Memorandum of Agreement (MOA), with a re-disclosure scheduled by August 25, 2026.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Explanation regarding Rumors or News Reports (Unconfirmed)
- Subject News Report: Celltrion to Build Chungnam Plant: “KRW 300B Investment by 2028” (Outlet: Seoul Economic Daily et al. / Date: Dec 1, 2023)
- Explanation & Chronology:
- Nov 30, 2023: Signed a Memorandum of Understanding (MOU) with Yesan-gun, Chungcheongnam-do for a KRW 300.0B biopharmaceutical & materials plant through Dec 2028
- Feb 27, 2025: Signed a Memorandum of Agreement (MOA) with Chungcheongnam-do, Yesan-gun, and Chungnam Development Corporation for a KRW 300.0B drug product (DP) plant
- Current Status: Unconfirmed (Details including investment period and amount are subject to change based on negotiations)
- Scheduled Re-disclosure Date: August 25, 2026 (To be re-disclosed upon finalization or within 6 months)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Final Investment Decision by Re-disclosure Date (August 25, 2026)
This filing is a periodic clarification disclosure regarding the reported KRW 300.0B drug product (DP) plant investment in Yesan, stating that specific terms following the MOA remain unconfirmed, making it important to monitor for a final re-disclosure by August 25, 2026. Tracking the transition from an MOA to a finalized investment decision ensures verification of the outcome of the corporate planning process. Finalized details can be verified through future clarification disclosures (Confirmed) or new facility investment filings prior to or on the re-disclosure date.
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
